跳至主要内容
临床试验/IRCT20080901001165N64
IRCT20080901001165N64尚未招募3 期

Evaluation of efficacy and safety of Glurunic acid (G2013) in patients with COVID-19

Ministry of Defense, Department of Health0 个研究点目标入组 180 人开始时间: 待定最近更新:
适应症

试验速览

阶段
3 期
状态
尚未招募
发起方
入组人数
180

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 years 至 65 years(—)
性别
All

入选标准

  • Confirmed diagnosis of COVID-19, with either lung CT-Scan result, which is typical for COVID-19 pulmonary involvement,or RT-PCR confirmation.
  • The patient/Legal guardian has written consciously and freely consent to participate in the study;
  • In the first 48 hours after his/her inclusion into this study, there is no possibility of discharge from the patient's hospital;
  • Moderate to severe COVID pneumonia

排除标准

  • The patient is present at another clinical trial at the same time.
  • Severe renal impairment
  • Severe hepatic impairment
  • Severe cardiac impairment
  • Uncontrolled diabetes
  • Active infection
  • Active cancer
  • Coagulopathy
  • Primary immunodeficiency syndrome
  • Allergy to Glurunic acid

研究者

发起方
Ministry of Defense, Department of Health

相似试验

Evaluation of efficacy and safety of Glurunic acid... | 临床试验